Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
September 18, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
September 13, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.

Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux...
September 07, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 10th Annual BioPharm America International Partnering Conference

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
August 31, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 31, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
August 17, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR...
August 10, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Provides 2017 Semi-Annual Business Update

RedHill’s U.S. gastrointestinal (GI)-focused sales force is promoting two specialty products, setting the stage for the potential launch of RedHill’s late clinical-stage GI products, if approved, and...
July 31, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease

The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the...
July 25, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports 2017 Second Quarter Financial Results

RedHill maintains a debt-free balance sheet with $51 million cash1 at the end of the second quarter of 2017 Select recent milestones include: Initial net revenues of approximately $0.5 million...
July 18, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017

TEL-AVIV, Israel and RALEIGH, N.C., July 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...